Guard Therapeutics International AB (publ), formerly A1M Pharma AB, is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-22	1.460 kr	-5.93%	7,903
26-06-18	1.552 kr	+2.11%	12,223
26-06-17	1.520 kr	-1.94%	11,656
26-06-16	1.550 kr	-2.52%	31,762

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-06-22 EDT			5-day change	1st Jan Change
1.460 ^SEK	-5.93%		-8.18%	-0.68%

06-12	Guard Therapeutics Initiates Divestment of GTX Platform	MT
06-11	Guard Therapeutics to Acquire Disruptive Pharma in Reverse Takeover	MT

Market Cap	29.44M 3.07M 2.68M 2.48M 2.31M 4.34M 290M 4.37M 11.46M 142M 11.51M 11.26M 495M	P/E 2026 *	0.63x	P/E 2027 *	0.56x
Enterprise Value	-86.56M -9.01M -7.87M -7.28M -6.8M -12.76M -852M -12.86M -33.68M -419M -33.83M -33.1M -1.45B	EV / Sales 2026 *	-0.7x	EV / Sales 2027 *	-1.16x
Free-Float	65.85%	Yield 2026 *	-	Yield 2027 *	-

06-12	Guard Therapeutics Initiates Divestment of GTX Platform	MT
06-11	Guard Therapeutics to Acquire Disruptive Pharma in Reverse Takeover	MT
06-11	Guard Therapeutics announces reverse takeover and planned name change	FW
05-11	Guard Therapeutics loss before and after tax SEK 6.4 mln	RE
05-11	Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-13	Seven stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
04-10	Three stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
03-31	Guard Therapeutics updates on strategic review	RE
03-31	Guard Therapeutics nears next phase of strategic review	FW
03-30	Guard Therapeutics International AB Provides Update on Strategic Review and Considers Multiple Strategic Alternatives	CI
02-20	Guard Therapeutics International net sales SEK 0 thousand	RE
02-20	Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-05	Guard Therapeutics International updates on strategic review	RE

25-10-26	Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study	CI
25-09-11	Redeye Initiates Coverage of Guard Therapeutics with Target Value of SEK 43	FW

Guard Therapeutics International AB Stock

Stocks

GUARD

SE0021181559

Biotechnology & Medical Research

Valuation: Guard Therapeutics International AB

Chart: Guard Therapeutics International AB

Latest news : Guard Therapeutics International AB

Last Transcript: Guard Therapeutics International AB

Analysts' recommendations: Guard Therapeutics International AB

Press Releases: Guard Therapeutics International AB

News in other languages: Guard Therapeutics International AB

Quotes and Performance

Course Extremes

Managers and Directors: Guard Therapeutics International AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-12	Guard Therapeutics Initiates Transaction Process for the GTX Platform	AQ
06-10	Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma	AQ
04-09	Guard Therapeutics provides information regarding observation status on Nasdaq First North Growth Market	AQ
03-31	Guard Therapeutics provides update on strategic review	AQ
02-05	Guard Therapeutics Announces Changes to the Company’s Management Team	AQ

21-04-07	ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG
21-04-07	ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Zahlungsberichten gemäß § 116 WpHG

1 day	-5.93%
1 week	-8.18%
Current month	+1.81%
1 month	+9.12%
3 months	-6.11%
6 months	-2.01%
Current year	-0.68%

1 week	1.35	1.6
1 month	1.2	2.14
Current year	0.88	2.35
1 year	0.88	27
3 years	0.88	49.8
5 years	0.88	112.5
10 years	0.88	3,050

Manager	Title	Age	Since
Tobias Larsson Agervald CEO	Chief Executive Officer	50	2019-01-14
Karin Botha DFI	Director of Finance/CFO	53	2020-09-13
Michael Reusch CTO	Chief Tech/Sci/R&D Officer	66	2021-12-31

Director	Title	Age	Since
Göran Forsberg BRD	Director/Board Member	63	2019-05-28
Johannes Hulthe BRD	Director/Board Member	56	2019-05-28
Johan Bygge CHM	Chairman	70	2021-04-30

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-02-27	Torbjörn Larsson	Free	Executive/Senior Manager	1,680,000	0.3339%
23-02-27	Peter Gilmour	Free		1,344,000	0.2672%
23-02-27	Tobias Larsson Agervald	Free	Chief Executive Officer	9,450,000	1.8784%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUARD THERAPEUTICS INTERNATIONAL AB	-5.93%	-8.18%	-91.34%	-76.36%	3.27M
LONZA GROUP AG	+0.34%	+1.09%	-10.67%	-5.05%	43.13B
REVOLUTION MEDICINES, INC.	+1.73%	+3.59%	+318.08%	+564.04%	34.65B
BEONE MEDICINES AG	+0.61%	+1.34%	+10.00%	+46.20%	30.03B
IQVIA HOLDINGS INC.	+0.02%	-5.93%	+8.45%	-21.44%	28B
CELLTRION, INC.	-1.06%	-3.71%	+9.08%	+19.56%	24.45B
ASCENDIS PHARMA A/S	-1.23%	+2.11%	-	-	14.34B
MEDPACE HOLDINGS, INC.	-0.99%	-2.53%	+47.29%	+102.88%	13.14B
EUROFINS SCIENTIFIC SE	+1.54%	+0.16%	+6.69%	+8.89%	12.53B
IONIS PHARMACEUTICALS, INC.	+2.39%	+2.61%	+102.86%	+84.20%	12.25B
Average	-0.26%	-1.06%	+44.49%	+80.32%	21.25B
Weighted average by Cap.	+0.40%	-0.22%	+67.03%	+116.48%

	2026 *	2027 *
Net sales	123M 12.81M 11.19M 10.35M 9.66M 18.14M 1.21B 18.27M 47.86M 595M 48.08M 47.04M 2.07B	123M 12.81M 11.19M 10.35M 9.66M 18.14M 1.21B 18.27M 47.86M 595M 48.08M 47.04M 2.07B
Net income	51M 5.31M 4.64M 4.29M 4.01M 7.52M 502M 7.58M 19.84M 247M 19.94M 19.5M 857M	58M 6.04M 5.28M 4.88M 4.56M 8.55M 571M 8.61M 22.57M 281M 22.67M 22.18M 975M
Net Debt	-116M -12.08M -10.55M -9.76M -9.11M -17.1M -1.14B -17.23M -45.13M -561M -45.34M -44.36M -1.95B	-172M -17.91M -15.65M -14.47M -13.51M -25.36M -1.69B -25.55M -66.92M -832M -67.24M -65.78M -2.89B